Greenwich LifeSciences/$GLSI
1D1W1MYTD1Y5YMAX
Capital at risk
About Greenwich LifeSciences
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
- Ticker
- $GLSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Stafford, United States
- Website
- greenwichlifesciences.com
GLSI Metrics
BasicAdvanced
$234M
-
-$1.58
1.45
-
Price and volume
Market cap
$234M
Beta
1.45
52-week high
$34.10
52-week low
$7.78
Average daily volume
125K
Financial strength
Current ratio
1.541
Quick ratio
1.541
Profitability
EBITDA (TTM)
-22.656
Management effectiveness
Return on assets (TTM)
-235.98%
Return on equity (TTM)
-986.32%
Valuation
Price to book
75.11
Price to tangible book (TTM)
75.11
Price to free cash flow (TTM)
-18.184
Free cash flow yield (TTM)
-5.50%
Free cash flow per share (TTM)
-0.877
Growth
Earnings per share change (TTM)
10.73%
3-year earnings per share growth (CAGR)
31.58%
What the Analysts think about GLSI
Analyst ratings (Buy, Hold, Sell) for Greenwich LifeSciences stock.
Analyst projections of the future price of Greenwich LifeSciences stock.
GLSI Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
GLSI News
AllArticlesVideos
Funds containing GLSI
Fund name | Fund size | $GLSI weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.